Barr Sues FDA Over Exclusivity for Generic Allegra-D

Law360, New York (February 5, 2005, 12:00 AM EST) -- Barr Laboratories has mounted a challenge to the way the U.S. Food and Drug Administration awards marketing exclusivity for new generics with a lawsuit seeking 180 days of exclusivity for its generic version of Aventis' allergy drug Allegra-D.

Under its existing policies, the FDA awards marketing exclusivity based on each patent filed in the Orange book, which can result in multiple companies having to share the exclusivity period when a drug has more than one patent, such as Allegra-D (fexofenadine HCl/pseudoephedrine HCl).

However, Barr's lawsuit, filed...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.